Joppa Pavol, Petrasova Darina, Stancak Branislav, Tkacova Ruzena
Department of Respiratory Medicine, Faculty of Medicine and L. Pasteur Teaching Hospital, Slovakia.
Chest. 2006 Aug;130(2):326-33. doi: 10.1378/chest.130.2.326.
COPD is a systemic disorder that is associated with increases of inflammatory proteins in systemic circulation. However, no data on the potential role of systemic inflammation in pulmonary hypertension secondary to COPD are available. Therefore, our aim was to investigate the degree of systemic inflammation reflected by circulatory levels of C-reactive protein (CRP), tumor-necrosis factor (TNF)-alpha, and interleukin (IL)-6 in COPD patients with and without pulmonary hypertension.
Cross-sectional study.
University hospital, tertiary referral setting.
In 43 consecutive patients with COPD (mean [+/- SD] age, 65.0 +/- 10.5 years; mean FEV(1), 46.2 +/- 18.1% predicted), lung function was assessed using body plethysmography; pulmonary artery pressure (Ppa) levels were measured by echocardiography. Serum TNF-alpha and IL-6 levels were assessed by enzyme-linked immunosorbent assay, and high-sensitivity serum CRP levels were measured by chemiluminescent immunoassay.
Pulmonary hypertension was present in 19 patients and was absent in 24 patients. In patients with pulmonary hypertension, serum CRP and TNF-alpha levels were significantly higher than in those patients without hypertension (median, 3.6 mg/L [25th to 75th percentile, 1.4 to 13.0 mg/L] vs 1.8 mg/L [25th to 75th percentile, 0.8 to 2.8 mg/L; p = 0.034]; and median, 4.2 pg/mL [25th to 75th percentile, 3.4 to 10.9 pg/mL] vs 3.1 pg/mL [25th to 75th percentile, 2.1 to 4.2 pg/mL]; p = 0.042, respectively). No differences were seen in serum IL-6 (median, 10.4 pg/mL [25th to 75th percentile, 8.8 to 12.2 pg/mL] vs 10.5 pg/mL [25th to 75th percentile, 9.4 to 39.1 pg/mL]; p = 0.651) between the groups. In multiple linear regression analysis, the following two variables were independent predictors of systolic Ppa (R(2) = 0.373): Pao(2) (p = 0.011); and log-transformed serum CRP level (p = 0.044).
We conclude that increases in Ppa in patients with COPD are associated with higher serum levels of CRP and TNF-alpha, raising the possibility of a pathogenetic role for low-grade systemic inflammation in the pathogenesis of pulmonary hypertension in COPD patients.
慢性阻塞性肺疾病(COPD)是一种全身性疾病,与全身循环中炎症蛋白增加有关。然而,目前尚无关于全身炎症在COPD继发肺动脉高压中潜在作用的数据。因此,我们的目的是研究伴或不伴肺动脉高压的COPD患者中,循环中C反应蛋白(CRP)、肿瘤坏死因子(TNF)-α和白细胞介素(IL)-6水平所反映的全身炎症程度。
横断面研究。
大学医院,三级转诊机构。
连续纳入43例COPD患者(平均[±标准差]年龄为65.0±10.5岁;平均第1秒用力呼气容积[FEV(1)]为预计值的46.2±18.1%),采用体描仪评估肺功能;通过超声心动图测量肺动脉压(Ppa)水平。采用酶联免疫吸附测定法评估血清TNF-α和IL-6水平,采用化学发光免疫测定法测量高敏血清CRP水平。
19例患者存在肺动脉高压,24例患者无肺动脉高压。在有肺动脉高压的患者中,血清CRP和TNF-α水平显著高于无肺动脉高压的患者(中位数分别为3.6 mg/L[第25至75百分位数,1.4至13.0 mg/L]与1.8 mg/L[第25至75百分位数,0.8至2.8 mg/L];p = 0.034];以及中位数分别为4.2 pg/mL[第25至75百分位数,3.4至10.9 pg/mL]与3.1 pg/mL[第25至75百分位数,2.1至4.2 pg/mL];p = 0.042)。两组间血清IL-6水平无差异(中位数分别为10.4 pg/mL[第25至75百分位数,8.8至12.2 pg/mL]与10.5 pg/mL[第25至75百分位数,9.4至39.1 pg/mL];p = 0.651)。在多元线性回归分析中,以下两个变量是收缩期Ppa的独立预测因素(R(2)=0.373):动脉血氧分压(Pao(2))(p = 0.011);以及经对数转换的血清CRP水平(p = 0.044)。
我们得出结论,COPD患者Ppa升高与血清CRP和TNF-α水平升高相关,这增加了低度全身炎症在COPD患者肺动脉高压发病机制中具有致病作用的可能性。